{"id":7061484,"date":"2026-09-19T22:38:41","date_gmt":"2026-09-19T22:38:41","guid":{"rendered":"https:\/\/peraltafinancing.com\/uncategorized\/novel-pharmacotherapies-for-opioid-use-disorder-and-opioid-withdrawal\/"},"modified":"2026-09-19T22:38:41","modified_gmt":"2026-09-19T22:38:41","slug":"novel-pharmacotherapies-for-opioid-use-disorder-and-opioid-withdrawal","status":"publish","type":"post","link":"https:\/\/fivemor.com\/?p=7061484","title":{"rendered":"Novel pharmacotherapies for opioid use disorder and opioid withdrawal"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div id=\"eng-abstract\">\n<p>        <strong class=\"sub-title\"><br \/>\n          Introduction:<br \/>\n        <\/strong><\/p>\n<p>      Opioid use disorder (OUD) remains a major public health crisis despite evidence-based medications, including methadone, buprenorphine, and naltrexone. Persistent challenges with treatment retention, access, stigma, and incomplete response highlight the need for adjunctive pharmacotherapies targeting neurobiological systems beyond the mu-opioid receptor.\n    <\/p>\n<p>        <strong class=\"sub-title\"><br \/>\n          Methods:<br \/>\n        <\/strong><\/p>\n<p>      We conducted a narrative review of emerging pharmacologic approaches for OUD and opioid withdrawal syndrome, focusing on ketamine and NMDA receptor antagonists, cannabinoids, psychedelics, and incretin-based therapies, including glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonists.\n    <\/p>\n<p>        <strong class=\"sub-title\"><br \/>\n          Results:<br \/>\n        <\/strong><\/p>\n<p>      Ketamine has preliminary randomized evidence suggesting potential effects on abstinence, withdrawal, craving, and psychotherapy augmentation. Cannabidiol may reduce cue-induced craving and anxiety, whereas dronabinol may modestly suppress opioid withdrawal symptoms. Psychedelic research, particularly involving ibogaine, shows observational signals for withdrawal reduction and abstinence but is limited by safety concerns, regulatory barriers, and sparse controlled evidence. Incretin-based therapies have generated strong observational signals linking GLP-1-based treatment to reduced overdose and OUD-related outcomes, though prospective trials remain limited.\n    <\/p>\n<p>        <strong class=\"sub-title\"><br \/>\n          Discussion:<br \/>\n        <\/strong><\/p>\n<p>      Across these therapeutic classes, convergent mechanisms include modulation of mesolimbic reward circuitry, cue-reactivity, stress responsivity, neuroplasticity, and cognitive flexibility. Future studies should prioritize rigorous blinding assessment, active comparators, objective endpoints, standardized cue-reactivity measures, diverse samples, and careful safety monitoring. Regulatory policies should facilitate the development and implementation of future research in novel therapies for OUD.\n    <\/p>\n<\/p><\/div>\n<p>        <strong class=\"sub-title\"><br \/>\n          Keywords:<br \/>\n        <\/strong><\/p>\n<p>      GLP-1; addiction; cannabinoid; drug; ketamine; opioid; psychedelics; withdrawal.\n    <\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>Introduction: Opioid use disorder (OUD) remains a major public health crisis despite evidence-based medications, including methadone, buprenorphine, and naltrexone. Persistent challenges with treatment retention, access, stigma, and incomplete response highlight the need for adjunctive pharmacotherapies targeting neurobiological systems beyond the mu-opioid receptor. Methods: We conducted a narrative review of emerging pharmacologic approaches for OUD and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":353883,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[135601],"tags":[15899,223518,223521,223520,223519,175060,175058,56813,175059,175057,41397,175056,25800,223522,223517,223516,175055,3749,55734],"dealstore":[],"offerexpiration":[],"class_list":["post-7061484","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-hemp","tag-disorder","tag-doi10-3389-fpsyt-2026-1909149","tag-joji-suzuki","tag-kwadwo-owusu-boaitey","tag-mary-r-shen","tag-medline","tag-national-center-for-biotechnology-information","tag-national-institutes-of-health","tag-national-library-of-medicine","tag-ncbi","tag-nih","tag-nlm","tag-opioid","tag-pharmacotherapies","tag-pmc13581858","tag-pmid42755825","tag-pubmed-abstract","tag-review","tag-withdrawal"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novel pharmacotherapies for opioid use disorder and opioid withdrawal - Som2ny Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fivemor.com\/?p=7061484\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novel pharmacotherapies for opioid use disorder and opioid withdrawal - Som2ny Network\" \/>\n<meta property=\"og:description\" content=\"Introduction: Opioid use disorder (OUD) remains a major public health crisis despite evidence-based medications, including methadone, buprenorphine, and naltrexone. Persistent challenges with treatment retention, access, stigma, and incomplete response highlight the need for adjunctive pharmacotherapies targeting neurobiological systems beyond the mu-opioid receptor. Methods: We conducted a narrative review of emerging pharmacologic approaches for OUD and [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fivemor.com\/?p=7061484\" \/>\n<meta property=\"og:site_name\" content=\"Som2ny Network\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-19T22:38:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/pubmed-meta-image-v2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"830\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fivemor.com\/?p=7061484#article\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/?p=7061484\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\"},\"headline\":\"Novel pharmacotherapies for opioid use disorder and opioid withdrawal\",\"datePublished\":\"2026-09-19T22:38:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=7061484\"},\"wordCount\":238,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/?p=7061484#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/pubmed-meta-image-v2.jpg\",\"keywords\":[\"Disorder\",\"doi:10.3389\/fpsyt.2026.1909149\",\"Joji Suzuki\",\"Kwadwo Owusu-Boaitey\",\"Mary R Shen\",\"MEDLINE\",\"National Center for Biotechnology Information\",\"National Institutes of Health\",\"National Library of Medicine\",\"NCBI\",\"NIH\",\"NLM\",\"Opioid\",\"pharmacotherapies\",\"PMC13581858\",\"pmid:42755825\",\"PubMed Abstract\",\"review\",\"withdrawal\"],\"articleSection\":[\"Hemp\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/fivemor.com\/?p=7061484#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fivemor.com\/?p=7061484\",\"url\":\"https:\/\/fivemor.com\/?p=7061484\",\"name\":\"Novel pharmacotherapies for opioid use disorder and opioid withdrawal - Som2ny Network\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=7061484#primaryimage\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/?p=7061484#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/pubmed-meta-image-v2.jpg\",\"datePublished\":\"2026-09-19T22:38:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fivemor.com\/?p=7061484#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fivemor.com\/?p=7061484\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/?p=7061484#primaryimage\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/pubmed-meta-image-v2.jpg\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/pubmed-meta-image-v2.jpg\",\"width\":1600,\"height\":830},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fivemor.com\/?p=7061484#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fivemor.com\/?bp_activities=1\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novel pharmacotherapies for opioid use disorder and opioid withdrawal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fivemor.com\/#website\",\"url\":\"https:\/\/fivemor.com\/\",\"name\":\"Som2ny Network\",\"description\":\"Daily Deals\",\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fivemor.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fivemor.com\/#organization\",\"name\":\"Som2ny Network\",\"url\":\"https:\/\/fivemor.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"width\":300,\"height\":86,\"caption\":\"Som2ny Network\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/fivemor.com\"],\"url\":\"https:\/\/fivemor.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novel pharmacotherapies for opioid use disorder and opioid withdrawal - Som2ny Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fivemor.com\/?p=7061484","og_locale":"en_US","og_type":"article","og_title":"Novel pharmacotherapies for opioid use disorder and opioid withdrawal - Som2ny Network","og_description":"Introduction: Opioid use disorder (OUD) remains a major public health crisis despite evidence-based medications, including methadone, buprenorphine, and naltrexone. Persistent challenges with treatment retention, access, stigma, and incomplete response highlight the need for adjunctive pharmacotherapies targeting neurobiological systems beyond the mu-opioid receptor. Methods: We conducted a narrative review of emerging pharmacologic approaches for OUD and [&hellip;]","og_url":"https:\/\/fivemor.com\/?p=7061484","og_site_name":"Som2ny Network","article_published_time":"2026-09-19T22:38:41+00:00","og_image":[{"width":1600,"height":830,"url":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/pubmed-meta-image-v2.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fivemor.com\/?p=7061484#article","isPartOf":{"@id":"https:\/\/fivemor.com\/?p=7061484"},"author":{"name":"admin","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371"},"headline":"Novel pharmacotherapies for opioid use disorder and opioid withdrawal","datePublished":"2026-09-19T22:38:41+00:00","mainEntityOfPage":{"@id":"https:\/\/fivemor.com\/?p=7061484"},"wordCount":238,"commentCount":0,"publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"image":{"@id":"https:\/\/fivemor.com\/?p=7061484#primaryimage"},"thumbnailUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/pubmed-meta-image-v2.jpg","keywords":["Disorder","doi:10.3389\/fpsyt.2026.1909149","Joji Suzuki","Kwadwo Owusu-Boaitey","Mary R Shen","MEDLINE","National Center for Biotechnology Information","National Institutes of Health","National Library of Medicine","NCBI","NIH","NLM","Opioid","pharmacotherapies","PMC13581858","pmid:42755825","PubMed Abstract","review","withdrawal"],"articleSection":["Hemp"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fivemor.com\/?p=7061484#respond"]}]},{"@type":"WebPage","@id":"https:\/\/fivemor.com\/?p=7061484","url":"https:\/\/fivemor.com\/?p=7061484","name":"Novel pharmacotherapies for opioid use disorder and opioid withdrawal - Som2ny Network","isPartOf":{"@id":"https:\/\/fivemor.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fivemor.com\/?p=7061484#primaryimage"},"image":{"@id":"https:\/\/fivemor.com\/?p=7061484#primaryimage"},"thumbnailUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/pubmed-meta-image-v2.jpg","datePublished":"2026-09-19T22:38:41+00:00","breadcrumb":{"@id":"https:\/\/fivemor.com\/?p=7061484#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fivemor.com\/?p=7061484"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/?p=7061484#primaryimage","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/pubmed-meta-image-v2.jpg","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/pubmed-meta-image-v2.jpg","width":1600,"height":830},{"@type":"BreadcrumbList","@id":"https:\/\/fivemor.com\/?p=7061484#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fivemor.com\/?bp_activities=1"},{"@type":"ListItem","position":2,"name":"Novel pharmacotherapies for opioid use disorder and opioid withdrawal"}]},{"@type":"WebSite","@id":"https:\/\/fivemor.com\/#website","url":"https:\/\/fivemor.com\/","name":"Som2ny Network","description":"Daily Deals","publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fivemor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fivemor.com\/#organization","name":"Som2ny Network","url":"https:\/\/fivemor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","width":300,"height":86,"caption":"Som2ny Network"},"image":{"@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","caption":"admin"},"sameAs":["https:\/\/fivemor.com"],"url":"https:\/\/fivemor.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/7061484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7061484"}],"version-history":[{"count":0,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/7061484\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/media\/353883"}],"wp:attachment":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7061484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7061484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7061484"},{"taxonomy":"dealstore","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fdealstore&post=7061484"},{"taxonomy":"offerexpiration","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fofferexpiration&post=7061484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}